FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1506042288> ?p ?o ?g. }

• W1506042288 endingPage "71" @default.
• W1506042288 startingPage "65" @default.
• W1506042288 abstract "CPX-351, a liposomal formulation of cytarabine and daunorubicin co-encapsulated at an optimized synergistic 5:1 molar ratio, has demonstrated improved clinical outcomes over conventional cytarabine/daunorubicin treatment in a randomized phase 2 trial in patients with AML as well as superior efficacy against preclinical leukemia models when compared to the free drugs in combination.Given the promising phase 2 data, limited toxicities observed, and the known clinical activities of cytarabine/daunorubicin, we assessed the efficacy of CPX-351 against a panel of childhood ALL xenograft models. Plasma pharmacokinetics of cytarabine and daunorubicin following CPX-351 treatment were determined by HPLC in order to correlate efficacy with drug exposure.CPX-351, at a dose of 5 units/kg (corresponding to 5 mg/kg cytarabine and 2.2 mg/kg daunorubicin), was highly efficacious against all xenografts tested, inducing complete responses in four B-lineage xenografts and partial response in one T-lineage xenograft. These therapeutic responses were achieved with CPX-351 doses that provided drug exposures (based on Cmax and AUC) comparable to those observed in patients with AML.These results suggest that CPX-351 may be a promising chemotherapeutic to be utilized in the treatment of ALL and support its testing in pediatric patients with leukemia." @default.
• W1506042288 created "2016-06-24" @default.
• W1506042288 creator A5020081255 @default.
• W1506042288 creator A5046943976 @default.
• W1506042288 creator A5050873964 @default.
• W1506042288 creator A5067801513 @default.
• W1506042288 creator A5073277560 @default.
• W1506042288 creator A5078917865 @default.
• W1506042288 creator A5080585542 @default.
• W1506042288 creator A5086725396 @default.
• W1506042288 date "2014-09-09" @default.
• W1506042288 modified "2023-10-06" @default.
• W1506042288 title "Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program" @default.
• W1506042288 cites W1571073982 @default.
• W1506042288 cites W1789507134 @default.
• W1506042288 cites W1897951801 @default.
• W1506042288 cites W1944430150 @default.
• W1506042288 cites W1970473877 @default.
• W1506042288 cites W1975309857 @default.
• W1506042288 cites W1982040265 @default.
• W1506042288 cites W1989882509 @default.
• W1506042288 cites W1995364339 @default.
• W1506042288 cites W1999705499 @default.
• W1506042288 cites W2001626458 @default.
• W1506042288 cites W2001772352 @default.
• W1506042288 cites W2040634930 @default.
• W1506042288 cites W2045977586 @default.
• W1506042288 cites W2055482234 @default.
• W1506042288 cites W2063432693 @default.
• W1506042288 cites W2070269177 @default.
• W1506042288 cites W2075532222 @default.
• W1506042288 cites W2082440968 @default.
• W1506042288 cites W2105435030 @default.
• W1506042288 cites W2111008003 @default.
• W1506042288 cites W2116858301 @default.
• W1506042288 cites W2136112505 @default.
• W1506042288 cites W2136923586 @default.
• W1506042288 cites W2141019574 @default.
• W1506042288 cites W2144672860 @default.
• W1506042288 cites W2144999788 @default.
• W1506042288 cites W2145112411 @default.
• W1506042288 cites W2145240921 @default.
• W1506042288 cites W2148428061 @default.
• W1506042288 cites W2162351643 @default.
• W1506042288 cites W4238407987 @default.
• W1506042288 cites W2044576633 @default.
• W1506042288 doi "https://doi.org/10.1002/pbc.25133" @default.
• W1506042288 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4237711" @default.
• W1506042288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25203866" @default.
• W1506042288 hasPublicationYear "2014" @default.
• W1506042288 type Work @default.
• W1506042288 sameAs 1506042288 @default.
• W1506042288 citedByCount "19" @default.
• W1506042288 countsByYear W15060422882015 @default.
• W1506042288 countsByYear W15060422882016 @default.
• W1506042288 countsByYear W15060422882017 @default.
• W1506042288 countsByYear W15060422882018 @default.
• W1506042288 countsByYear W15060422882019 @default.
• W1506042288 countsByYear W15060422882020 @default.
• W1506042288 countsByYear W15060422882022 @default.
• W1506042288 countsByYear W15060422882023 @default.
• W1506042288 crossrefType "journal-article" @default.
• W1506042288 hasAuthorship W1506042288A5020081255 @default.
• W1506042288 hasAuthorship W1506042288A5046943976 @default.
• W1506042288 hasAuthorship W1506042288A5050873964 @default.
• W1506042288 hasAuthorship W1506042288A5067801513 @default.
• W1506042288 hasAuthorship W1506042288A5073277560 @default.
• W1506042288 hasAuthorship W1506042288A5078917865 @default.
• W1506042288 hasAuthorship W1506042288A5080585542 @default.
• W1506042288 hasAuthorship W1506042288A5086725396 @default.
• W1506042288 hasBestOaLocation W15060422882 @default.
• W1506042288 hasConcept C112705442 @default.
• W1506042288 hasConcept C126322002 @default.
• W1506042288 hasConcept C143998085 @default.
• W1506042288 hasConcept C22979827 @default.
• W1506042288 hasConcept C2778041864 @default.
• W1506042288 hasConcept C2778461978 @default.
• W1506042288 hasConcept C2781021840 @default.
• W1506042288 hasConcept C71924100 @default.
• W1506042288 hasConcept C98274493 @default.
• W1506042288 hasConceptScore W1506042288C112705442 @default.
• W1506042288 hasConceptScore W1506042288C126322002 @default.
• W1506042288 hasConceptScore W1506042288C143998085 @default.
• W1506042288 hasConceptScore W1506042288C22979827 @default.
• W1506042288 hasConceptScore W1506042288C2778041864 @default.
• W1506042288 hasConceptScore W1506042288C2778461978 @default.
• W1506042288 hasConceptScore W1506042288C2781021840 @default.
• W1506042288 hasConceptScore W1506042288C71924100 @default.
• W1506042288 hasConceptScore W1506042288C98274493 @default.
• W1506042288 hasIssue "1" @default.
• W1506042288 hasLocation W15060422881 @default.
• W1506042288 hasLocation W15060422882 @default.
• W1506042288 hasLocation W15060422883 @default.
• W1506042288 hasLocation W15060422884 @default.
• W1506042288 hasOpenAccess W1506042288 @default.
• W1506042288 hasPrimaryLocation W15060422881 @default.
• W1506042288 hasRelatedWork W1964648983 @default.
• W1506042288 hasRelatedWork W1991965294 @default.

• next